Task: Answer Verification
Input (English): Question: Does rosiglitazone improve vascular function in subjects with chronic kidney disease?
Answer: Short-term RSG therapy reduced insulin resistance, in vivo markers of inflammation and abnormal endothelial function but had no effect on arterial function and stiffness in patients with CKD.
Output (English): no